BioVaxys

What BioVaxys does

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, publicly listed on the Canadian Securities Exchange (BIOV), Frankfurt Bourse (5LB), and OTCQB (BVAXF). Founded in 2018, the company is focused on developing and out-licensing immunotherapeutic assets built on its proprietary DPX™ (formerly IMV) antigen delivery platform, a non-aqueous, lipid-in-oil formulation that does not release active ingredients at the injection site but instead forces active uptake into immune cells and lymph nodes, enabling sustained, targeted immune responses without systemic side effects. BioVaxys' lead clinical asset is Maveropepimut-S (MVP-S), a DPX-formulated survivin-targeting cancer vaccine with Phase 2B data showing a 21% overall response rate and 63% disease control rate in recurrent ovarian cancer, complete responses in 3 of 6 evaluable relapsed/refractory DLBCL patients when combined with pembrolizumab, and positive Phase 2 data in metastatic bladder cancer. The pipeline also includes the HapTenix© personalized neoantigen platform (BVX-0918 for refractory ovarian cancer), DPX+SurMAGE dual-targeted immunotherapy, DPX-RSV for infectious disease, and DPX+rPA for peanut allergy prophylaxis.

The company operates through three revenue channels: (1) out-licensing of DPX-based immunotherapy assets to global pharma partners, with active out-licensing initiated for ovarian cancer and DLBCL; (2) royalty-bearing license agreements with third parties including SpayVac-for-Wildlife (wildlife contraception), Zoetis (animal health), and Merck KGaA (survivin proteins), with a 6% gross sales royalty and 15% share in license revenues stemming from the February 2024 IMV asset acquisition; and (3) exclusive US distribution of OTC women's reproductive health products (Papilocare®) sourced from Barcelona-based Procare Health Iberia. BioVaxys holds 120+ patents across 25 distinct patent families acquired from IMV Inc., supplemented by exclusive patents in haptenized vaccine technologies originating from Dr. David Berd's work at Thomas Jefferson University.

The company's commercial strategy is sales-led and B2B-oriented, relying on enterprise licensing relationships rather than direct product commercialization. The lead clinical asset MVP-S was acquired via the February 2024 IMV asset purchase (USD $750,000 upfront) and is being positioned for out-licensing to global pharma partners. Revenue is pre-commercial; the company has sustained operations through repeated private placements and convertible debentures, with a CAD $1.92M LIFE private placement completed in November 2025 and use-of-proceeds explicitly earmarked for licensing pursuits. The company has 1-10 employees and operates lean offices in Vancouver (registered), Etobicoke (contact), North Miami (US OTC distribution), and a listed New York address. Leadership comprises CEO James Passin, President & COO Kenneth Kovan, and Director Dr. James Tartaglia (former Sanofi Global Head of Vaccine Development).

Name

BioVaxys

Legal name

BioVaxys Technology Corp.

Website

https://biovaxys.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company developing and out-licensing immunotherapeutic cancer vaccines built on its proprietary DPX™ lipid-in-oil antigen delivery platform, with Phase 2B lead asset Maveropepimut-S targeting ovarian cancer, DLBCL, and bladder cancer, plus royalty-bearing licenses with Zoetis, SpayVac, and Merck KGaA.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals / cancer immunotherapy vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Cancer immunotherapy vaccines
• Antigen delivery platform
• Clinical-stage biopharmaceuticals
• Lipid-in-oil formulation
• Out-licensing therapeutics

Headquarters

HQ city

Etobicoke

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Out-licensing of DPX-based immunotherapy assets: BioVaxys is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets developed from its proprietary DPX™ platform. Out-licensing has been initiated for both ovarian cancer and DLBCL indications. Revenue is pre-commercial, expected as upfront payments, milestones, and royalties upon out-licensing.
2. Royalty and milestone-bearing licenses with third parties: Royalty-bearing License and Supply Agreement with SpayVac for Wildlife Inc. on sales of animal vaccine products; milestone payments and royalty bearing license agreement with Zoetis Inc. for various animal health products; license with Merck KGaA for survivin proteins. Includes a 15% share in license revenues and a 6% gross sales royalty on product sales (cancellable upon one-time USD$25M cash payment) from the IMV asset acquisition.
3. OTC women's healthcare products distribution: BioVaxys is the exclusive US licensee and distributor of a portfolio of OTC female reproductive health products currently marketed in the EU from Barcelona-based Procare Health Iberia, including Papilocare® and Papilocare® Immunocaps. Pre-revenue/limited distribution in the US market.
4. Sale of medical software assets (one-time): In June 2023, BioVaxys sold TAET Software Co. to 10402588 BC Ltd for 500,000 shares of the Purchaser, with potential future milestone payments totaling a maximum of 1,000,000 shares and a maximum of USD$4,000,000 in cash.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

BioVaxys develops and out-licenses clinical-stage immunotherapy assets built on its proprietary DPX™ lipid-in-oil antigen delivery platform. Its pipeline includes Maveropepimut-S (MVP-S) for ovarian cancer, DLBCL, bladder cancer, and breast cancer, plus BVX-0918 (personalized HapTenix© vaccine), DPX+SurMAGE, DPX-RSV, and DPX+rPA for peanut allergy. The company generates revenue through licensing upfronts, milestone payments, and royalties from partners such as Zoetis, Merck KGaA, and SpayVac-for-Wildlife, and additionally distributes OTC women's health products (Papilocare®) under exclusive US rights.

Differentiator

Problem solved

Functional benefit

Brands

• DPX™: Proprietary lipid-in-oil antigen delivery and immune-educating technology platform that does not release active ingredients at the injection site but forces active uptake into immune cells and lymph nodes for sustained, targeted immune responses. Compatible with peptides, proteins, mRNA, virus-like particles, and small molecules.
• HapTenix©
• Maveropepimut-S (MVP-S)
• BVX-0918
• DPX+SurMAGE
• DPX-RSV
• DPX+rPA

Products and services

• DPX™ Delivery Platform
• Maveropepimut-S (MVP-S)
• BVX-0918
• DPX+SurMAGE
• DPX-RSV
• DPX+rPA
• Papilocare® / Papilocare® Immunocaps

Quantifiable outcome

• 21% overall response rate and 63% disease control rate in recurrent ovarian cancer with MVP-S
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

17 partnerships are on record, tiered core (emerging r&d collaboration), core (clinical research partner), supporting (research collaboration), core (licensee), major (board of directors), flagship / transformational, major (global animal health leader), core (license for survivin proteins), core (otc distribution supplier), minor (asset sale), supporting (research partner, logo displayed), core (academic origin), supporting (logo display) and supporting (research partner).

• Adiverna LLCcore (emerging r&d collaboration)Strategic or Co-development Partner · 10 March 2026Research Agreement to develop mRNA-based vaccines for companion animals (dogs and cats) targeting Rabies, Leptospirosis, and Feline Infectious Peritonitis, among others. Collaboration combines BioVaxys' DPX Immune Educating Platform with Adiverna's AI-designed mRNA sequences. Addresses a market gap since no mRNA vaccines are currently approved for dogs and cats. Aims to enhance vaccine safety, effectiveness, and dosing efficiency for routine pet vaccinations.
• Quantum Santa Fe / University of New Mexico Comprehensive Cancer Centercore (clinical research partner)Implementation/ SI/ Consulting Partner · 29 January 2026Phase 2 clinical study of MVP-S + pembrolizumab + low-dose cyclophosphamide in metastatic bladder cancer led by Oliver Rix, MD, PhD (Founder, Director, and Principal Investigator at Quantum Santa Fe, and Clinical Research Professor of Medicine at the University of New Mexico Comprehensive Cancer Center).
• McMaster Universitysupporting (research collaboration)Strategic or Co-development Partner · 30 October 2025Initiation of DPX food allergy program at McMaster University for conducting a preclinical proof of concept study with a DPX peanut antigen prophylaxis vaccine candidate. Funded by LIFE private placement proceeds.
• SpayVac-for-Wildlife, Inc.core (licensee)OEM/ Whitelabel/ Licensing Partner · 14 October 2025Royalty-bearing License and Supply Agreement with SpayVac-for-Wildlife, Inc. (Madison, Wisconsin) for sales of animal vaccine products using BioVaxys' patented liposome-based delivery platform. In Bavarian Forest National Park Germany study published in European Journal of Wildlife Research, a single dose of SpayVac significantly reduced fertility to 11% in vaccinated deer vs 86% in control animals. SpayVac is clinically validated in fallow deer, white-tailed deer, and red deer. SpayVac has initiated regulatory submission for feral horses and free-ranging deer populations.
• James Tartaglia, PhD (formerly Sanofi Vaccines)major (board of directors)Strategic or Co-development Partner · 8 October 2025Former Global Head of Vaccine Development and Life Cycle Management at Sanofi with 34 years of industry experience; inventor on over 20 patents; appointed to BioVaxys Board of Directors (filling vacancy from Anthony Dutton's resignation). Founder of Tartaglia Consulting, LLC. Involved in licensure of 20 vaccines in veterinary and human health; portfolio of 25 vaccine projects across influenza, pediatric combination vaccines, RSV, rabies, Yellow Fever, pneumococcal, and meningococcal.
• IMV Inc. (Immunovaccine Technologies Inc. and IMV USA)flagship / transformationalStrategic or Co-development Partner · 12 February 2024BioVaxys executed a definitive Asset Purchase Agreement dated February 11, 2024 to acquire the entire portfolio of discovery, preclinical, and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology developed by IMV. Transaction elements include USD$750,000 upfront cash, clinical development and regulatory milestone payments, 15% share in license revenues, 6% gross sales royalty on product sales (cancellable upon USD$25M payment), shares of BioVaxys common stock valued at US$250,000, and HIMV's right to appoint a Board observer. Kenneth Kovan called this an 'absolutely transformational transaction.'
• Zoetis Inc.major (global animal health leader)OEM/ Whitelabel/ Licensing Partner · 12 February 2024Milestone payments and royalty bearing license agreement with Zoetis Inc., the Pfizer animal health spin-out and the world's largest producer of medicine and vaccinations for pets and livestock, for their development and sale of various animal health products using the technology acquired by BioVaxys.
• Merck KGaA (German pharmaceuticals company)core (license for survivin proteins)OEM/ Whitelabel/ Licensing Partner · 12 February 2024License agreement with German pharmaceuticals company Merck KGaA for survivin proteins. Survivins are highly expressed in most cancers and are associated with a poor clinical outcome, making them a significant target for cancer therapeutics.
• Procare Health Iberiacore (otc distribution supplier)Channel Partner/ Reseller/ Distributor · 15 June 2023Barcelona-based Procare Health Iberia supplies BioVaxys with OTC female reproductive health products (Papilocare® re-epithelializing vaginal gel and Papilocare® Immunocaps) currently marketed in the EU. BioVaxys holds exclusive US distribution rights for these products.
• 10402588 BC Ltdminor (asset sale)Others · 15 June 2023Private company formed under the laws of British Columbia that purchased TAET Software Co. from BioVaxys in exchange for 500,000 shares of the Purchaser, with potential future milestone payments totaling a maximum of 1,000,000 shares and a maximum of USD$4,000,000 in cash.
• NIH (National Institutes of Health)supporting (research partner, logo displayed)Strategic or Co-development PartnerPartner organization referenced via logo on the BioVaxys homepage partner collaboration section.
• Thomas Jefferson Universitycore (academic origin)Strategic or Co-development PartnerBioVaxys builds upon the pioneering work in protein haptenization by Dr. David Berd at Thomas Jefferson University and his previous vaccine development at Avax Technologies, Inc. Referenced via logo on partner collaboration section.
• Merck (referenced via logo)supporting (logo display)Strategic or Co-development PartnerPartner institution referenced via logo on the BioVaxys homepage partner collaboration section.
• CHU-Québecsupporting (research partner)Strategic or Co-development PartnerPartner institution referenced via logo on the BioVaxys homepage partner collaboration section.
• Dalhousie Universitysupporting (research partner)Strategic or Co-development PartnerPartner institution referenced via logo on the BioVaxys homepage partner collaboration section.
• Ohio State Universitysupporting (research partner)Strategic or Co-development PartnerPartner institution referenced via logo on the BioVaxys homepage partner collaboration section.
• UConn (University of Connecticut)supporting (research partner)Strategic or Co-development PartnerPartner institution referenced via logo on the BioVaxys homepage partner collaboration section.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Arcturus Therapeutics: Clinical-stage mRNA therapeutics company with proprietary LUNAR® lipid-mediated delivery platform. Direct comparison point for BioVaxys' DPX platform claim of superior mRNA delivery over LNPs; both target infectious disease and rare disease indications with proprietary non-LNP delivery technologies.
• Heat Biologics: Clinical-stage immunotherapy company developing T cell-stimulating therapeutic vaccines for cancer and infectious disease using a proprietary gp96-based platform. Comparable to BioVaxys in size, clinical stage, oncology focus, and out-licensing/strategic partnership business model.
• CureVac: mRNA technology company developing vaccines and therapeutics with proprietary LNPs and natural mRNA constructs. Direct peer in mRNA delivery where BioVaxys' DPX platform claims superior stability over LNPs and addresses the same clinical-stage vaccine indications including oncology and infectious disease.
• Werewolf Therapeutics: Clinical-stage oncology biopharmaceutical company developing a pipeline of PREDATOR™ prodrugs designed to deliver immune-stimulating payloads to the tumor microenvironment. Comparable to BioVaxys in size, clinical stage, and proprietary platform approach to tumor-targeted immunotherapy.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company with proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform. Comparable to BioVaxys in size, clinical stage, oncology focus, and platform-based approach with pipeline of targeted immunotherapies.
• Adaptimmune: Clinical-stage cell therapy company developing SPEAR T-cells for solid tumors with strategic partnership focus. Comparable to BioVaxys in clinical-stage oncology focus and partnership-driven business model, though operating in cell therapy rather than vaccine delivery.

Broad incumbents

• Moderna: Global mRNA leader with proprietary LNP-based delivery platform and broad oncology vaccine pipeline. Most direct reference competitor for BioVaxys' positioning that DPX is superior to LNPs for mRNA delivery; provides market context for the value of mRNA delivery technology, though at vastly larger scale.
• BioNTech: Global mRNA therapeutics leader with LNP-based delivery and a broad oncology vaccine pipeline including individualized neoantigen approaches. Comparable technology positioning to BioVaxys' mRNA delivery narrative; operates at much larger scale with multiple Phase 2/3 oncology assets.
• Novavax: Commercial-stage vaccine biotechnology company with proprietary recombinant nanoparticle vaccine platform (Matrix-M adjuvant). Comparable technology category to BioVaxys' DPX delivery platform; much larger and commercial-stage, providing context for how vaccine delivery technology platforms can scale.
• Dynavax Technologies: Commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with proprietary CpG 1018 adjuvant used in HEPLISAV-B hepatitis B vaccine. Comparable vaccine platform technology to BioVaxys' DPX delivery approach; larger and commercial-stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/biovaxys
• LinkedInlinkedin.com/company/biovaxys-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds19 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVaxys